1. Home
  2. ERAS vs CIX Comparison

ERAS vs CIX Comparison

Compare ERAS & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • CIX
  • Stock Information
  • Founded
  • ERAS 2018
  • CIX 1993
  • Country
  • ERAS United States
  • CIX United States
  • Employees
  • ERAS 129
  • CIX N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • CIX Industrial Machinery/Components
  • Sector
  • ERAS Health Care
  • CIX Consumer Discretionary
  • Exchange
  • ERAS Nasdaq
  • CIX Nasdaq
  • Market Cap
  • ERAS 413.6M
  • CIX 301.8M
  • IPO Year
  • ERAS 2021
  • CIX 1998
  • Fundamental
  • Price
  • ERAS $1.42
  • CIX $26.76
  • Analyst Decision
  • ERAS Strong Buy
  • CIX
  • Analyst Count
  • ERAS 6
  • CIX 0
  • Target Price
  • ERAS $4.83
  • CIX N/A
  • AVG Volume (30 Days)
  • ERAS 1.1M
  • CIX 8.5K
  • Earning Date
  • ERAS 08-11-2025
  • CIX 08-05-2025
  • Dividend Yield
  • ERAS N/A
  • CIX 4.56%
  • EPS Growth
  • ERAS N/A
  • CIX N/A
  • EPS
  • ERAS N/A
  • CIX 1.46
  • Revenue
  • ERAS N/A
  • CIX $148,242,000.00
  • Revenue This Year
  • ERAS N/A
  • CIX N/A
  • Revenue Next Year
  • ERAS N/A
  • CIX N/A
  • P/E Ratio
  • ERAS N/A
  • CIX $18.29
  • Revenue Growth
  • ERAS N/A
  • CIX N/A
  • 52 Week Low
  • ERAS $1.01
  • CIX $17.89
  • 52 Week High
  • ERAS $3.45
  • CIX $36.10
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 53.15
  • CIX 57.16
  • Support Level
  • ERAS $1.42
  • CIX $25.51
  • Resistance Level
  • ERAS $1.58
  • CIX $28.95
  • Average True Range (ATR)
  • ERAS 0.10
  • CIX 1.38
  • MACD
  • ERAS 0.01
  • CIX 0.13
  • Stochastic Oscillator
  • ERAS 68.65
  • CIX 45.39

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

Share on Social Networks: